We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Metabolomics Profiles Associated with Diabetic Retinopathy

By LabMedica International staff writers
Posted on 16 Nov 2020
Print article
Image: The AbsoluteIDQ p180 kit provides scientists with highly reproducible metabolomics data to confidently obtain detailed knowledge about the metabolic phenotypes in their studies (Photo courtesy of BIOCRATES Life Sciences).
Image: The AbsoluteIDQ p180 kit provides scientists with highly reproducible metabolomics data to confidently obtain detailed knowledge about the metabolic phenotypes in their studies (Photo courtesy of BIOCRATES Life Sciences).
Diabetic retinopathy (DR), like diabetic neuropathy and nephropathy, is a common complication of diabetes. It is the leading cause of loss of vision in diabetic patients. Long-standing disease, along with hyperglycemia, hyperlipidemia, hypertension, and genetic factors, is a major risk factor of diabetes retinopathy.

Metabolomics profiling is a rapidly evolving method used to identify the metabolites in biological fluids and investigate disease progression. Quantitative analyses of small-molecule metabolites in biological specimens such as blood and urine can be performed due to the rapid advances in metabolomics.

Medical Scientists at the Chungbuk National University College of Medicine (Cheongju, Republic of Korea) included in a study 317 type 2 diabetes (T2D) patients of which 143 non-DR (NDR) patients, 123 non- proliferative DR (NPDR) patients, and 51 proliferative-DR (PDR) patients. Gender, age, height, weight, body mass index (BMI), and HbA1c, glucose, and creatinine levels of all patients were recorded.

The serum samples of the T2D patients were analyzed using a targeted metabolomics approach. To quantify the metabolites, liquid chromatography (LC) and flow-injection analysis (FIA)–mass spectrometry (MS) were performed using the AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences AG, Innsbruck, Austria). The serum samples were analyzed using the API 4000 QTRAP LC/MS/MS system (Applied Biosystems, Foster City, CA, USA) and the Agilent 1200 HPLC system (Agilent Technologies, Santa Clara, CA, USA).

The investigators reported that the concentrations of 62 metabolites of the NDR versus DR group, 53 metabolites of the NDR versus NPDR group, and 30 metabolites of the NDR versus PDR group were found to be significantly different. Sixteen metabolites were selected as specific metabolites common to NPDR and PDR. Among them, three metabolites including total dimethylarginine, tryptophan, and kynurenine were potential makers of DR progression in T2D patients. Additionally, several metabolites such as carnitines, several amino acids, and phosphatidylcholines also showed a biomarker potential.

The authors concluded that they had revealed via comprehensive metabolomics profiling using a high-throughput platform, several metabolites associated with DR. These new DR-related metabolites should be considered in the study of the mechanism behind the initiation and progression of DR in T2D patients. The study was published on October 29, 2020 in the journal PLOS ONE.

Related Links:
Chungbuk National University College of Medicine
BIOCRATES Life Sciences
Applied Biosystems
Agilent Technologies



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.